Fragment based drug design

Fragment based drug design (FBDD) is a strategy for lead discovery that is growing rapidly in popularity. Rather than rely on gargantuan libraries of hundreds of thousands of complex molecules, FBDD revolves around a small, carefully curated library of very small molecules that are about half the size of typical drugs. A target protein is screened against the library and ‘hits’ can then be chemically expanded to create lead compounds that bind with high affinity. The approach can be used to target enzymes as well as less traditional targets such as protein-protein or protein nucleic acid interactions. FBDD is likely to be a vital resource in the search for new antimicrobial compounds.

Our FBDD facility acts as the Sydney node of the established FBDD platform at Monash University run by A/Prof Martin Scanlon. Our facility consists of a Janus liquid handling robot and a cryoprobe-equipped 600-MHz NMR spectrometer fitted with a SampleJet autosampler. This setup allows us to prepare and screen a large amount of samples.

Please contact to discuss how your research could benefit from a fragment based drug design approach.